Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy NeuroPace stock (NeuroPace)

Buy NeuroPace stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

NeuroPace is a medical devices business based in the US. NeuroPace shares (NPCE) are listed on the NASDAQ and all prices are listed in US Dollars. NeuroPace employs 181 staff and has a trailing 12-month revenue of around $69.1 million.

Our top picks for where to buy Neuropace stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy NeuroPace stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – NPCE. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy NeuroPace stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Not rated yet
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

NeuroPace stock price (NASDAQ: NPCE)

Use our graph to track the performance of NPCE stocks over time.

NeuroPace shares at a glance

Information last updated 2024-07-14.
Latest market close$7.70
52-week range$3.91 - $18.15
50-day moving average $7.94
200-day moving average $10.53
Wall St. target price$17.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.18

Is it a good time to buy NeuroPace stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NeuroPace price performance over time

Historical closes compared with the close of $7.7 from 2024-07-15

1 week (2024-07-10) 12.08%
1 month (2024-06-17) 18.46%
3 months (2024-04-17) -44.00%
6 months (2024-01-17) -40.77%
1 year (2023-07-17) 83.77%
2 years (2022-07-15) 34.15%
3 years (2021-07-16) 23.29
5 years (2019-07-13) N/A

NeuroPace financials

Revenue TTM $69.1 million
Gross profit TTM $32.5 million
Return on assets TTM -16.09%
Return on equity TTM -150.63%
Profit margin -45.61%
Book value $0.50
Market Capitalization $214 million

TTM: trailing 12 months

NeuroPace share dividends

We're not expecting NeuroPace to pay a dividend over the next 12 months.

NeuroPace share price volatility

Over the last 12 months, NeuroPace's shares have ranged in value from as little as $3.91 up to $18.15. A popular way to gauge a stock's volatility is its "beta".

NPCE.US volatility(beta: 1.81)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeuroPace's is 1.811. This would suggest that NeuroPace's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put NeuroPace's beta into context you can compare it against those of similar companies.

NeuroPace overview

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc.

Frequently asked questions

What percentage of NeuroPace is owned by insiders or institutions?
Currently 4.254% of NeuroPace shares are held by insiders and 79.351% by institutions.
How many people work for NeuroPace?
Latest data suggests 181 work at NeuroPace.
When does the fiscal year end for NeuroPace?
NeuroPace's fiscal year ends in December.
Where is NeuroPace based?
NeuroPace's address is: 455 North Bernardo Avenue, Mountain View, CA, United States, 94043
What is NeuroPace's ISIN number?
NeuroPace's international securities identification number is: US6412881053

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site